...
首页> 外文期刊>Medical oncology >Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer
【24h】

Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer

机译:KRAS和PIK3CA突变是大肠癌远处转移的独立预测因子

获取原文
获取原文并翻译 | 示例
           

摘要

The objective was to evaluate DNA mutations of KRAS, BRAF, and PIK3CA and their clinicopathological correlations with colorectal cancer (CRC) and to identify their contribution to distant metastases in CRC. A total of 148 tumor samples were obtained from patients with CRC in the Shandong Tumor Hospital and Institute between January 2008 and December 2009. DNA was extracted for polymerase chain reaction amplification and pyrosequencing to evaluate mutations of KRAS, BRAF, and PIK3CA, and clinicopathological correlations of these mutations with CRC [including age, gender, tumor location, pathological type, tumor-node-metastasis (TNM) classification, and distant metastatic status] were analyzed. KRAS, BRAF, and PIK3CA mutation rates were identified in 46 (31.1 %), 11 (7.4 %), and 14 (9.5 %) of the total 148 CRC tumor samples, respectively. Neither mutation had significant correlation with age, gender, size and location of the tumor, and pathological type. KRAS, BRAF, and PIK3CA mutations were found in 14 (66.7 %), 3 (14.3 %), and 8 (38.1 %) of the 21 distant metastatic colorectal tumor samples, respectively. The relative risks of distant metastasis for KRAS, BRAF, and PIK3CA mutations were 30.4 versus 6.8 % (P = 0.001), 27.3 versus 13.1 % (P = 0.191), and 57.1 versus 9.7 % (P< 0.001) (5-year risks), respectively. Patients with either KRAS or PIK3CA mutations are more susceptible to distant metastasis. Thus, these two mutations might be used as independent predictors of distant metastatic CRC.
机译:目的是评估KRAS,BRAF和PIK3CA的DNA突变及其与结直肠癌(CRC)的临床病理相关性,并确定其对CRC远处转移的影响。在2008年1月至2009年12月间,从山东省肿瘤医院和研究所的CRC患者中总共获得148个肿瘤样品。提取DNA进行聚合酶链反应扩增和焦磷酸测序,以评估KRAS,BRAF和PIK3CA的突变以及临床病理相关性分析了这些带有CRC的突变[包括年龄,性别,肿瘤位置,病理类型,肿瘤淋巴结转移(TNM)分类和远处转移状态]。在148个CRC肿瘤样本中分别确定了46个(31.1%),11个(7.4%)和14个(9.5%)的KRAS,BRAF和PIK3CA突变率。两种突变均与年龄,性别,肿瘤的大小和位置以及病理类型无显着相关性。在21个远处转移性结直肠肿瘤样本中,分别在14个(66.7%),3个(14.3%)和8个(38.1%)中发现了KRAS,BRAF和PIK3CA突变。 KRAS,BRAF和PIK3CA突变远距离转移的相对风险分别为30.4比6.8%(P = 0.001),27.3比13.1%(P = 0.191)和57.1比9.7%(P <0.001)(5年风险) ), 分别。具有KRAS或PIK3CA突变的患者更容易发生远处转移。因此,这两个突变可用作远处转移性CRC的独立预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号